[Skip navigation] FDA Logo links to FDA home page
Center for Drug Evaluation and Research, U.S. Food and Drug AdministrationU.S. Food and Drug AdministrationCenter for Drug Evaluation and Research
 HHS Logo links to Department of Health and Human Services website

FDA Home Page | CDER Home Page | CDER Site Info | Contact CDER | What's New @ CDER

horizonal rule

Drug Safety Oversight Board Meeting
October 26, 2006 Public Summary

  • The Executive Director updated the Board on Information Sheets and Public Health Advisories (PHAs) posted since the last meeting regarding the drugs lamotrigine (Lamictal) and aprotinin (Trasylol). The new sheets, PHAs, and other safety information were announced through MedWatch as well as under News from CDER

  • The Board received updates about ongoing topics including the risk of adverse events following use of fluoroquinolone antibiotics, and use of agents to treat macular degeneration. Adverse events associated with fluoroquinolones have been the subject of two citizen petitions.

  • The Board heard presentations on the history of Agency communication with patients/consumers and healthcare providers, and on the communication tools currently employed by CDER to provide information to those groups. It discussed the range of risk communication documents now in use and how to focus a risk communication strategy for the Center.

  DSOB Meeting Summaries

Date created: December 13, 2006   

horizonal rule

CDER Home Page | CDER Site Info | Contact CDER | What's New @ CDER
FDA Home Page | Search FDA Site | FDA A-Z Index | Contact FDA | Privacy | Accessibility | HHS Home Page

FDA/Center for Drug Evaluation and Research